Their results have demonstrated that CD38 is upregulated in HCC cell-bearing mice with resistance to PD-1/PD-L1 inhibitor, and EVs/siCD38 reversed the resistance to PD-1/PD-L1 inhibitor in mice. Here, CD38 is linked to hepatocellular carcinoma.